Key facts
- Notable investors include HSG (Hong Kong), Shenzhen Yifeng Investment Management Enterprise, Xiamen Hi-Tech Innovation Center, Paeonia Group, Beijing Zhenghe Zhengxin Investment Management — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Asia Regenerative Medicine
- ·The full record, as it builds
Funding rounds
No funding rounds for Asia Regenerative Medicine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Asia Regenerative Medicine
Developer of stem cell and tissue engineering technologies focused on addressing kidney disease. The company specailises in stem cells, exosomes, dialysis enhancement therapies, implantable bioartificial kidneys and differentiated cell platforms, enabling solutions for chronic kidney disease, end-stage renal failure, and organ transplant shortages.
- Sector
- Healthcare
- HQ
- Shenzhen, China
- Founded
- 2018
- Employees
- 100
- Website
- asiaregen.com/
- Ownership
- Privately Held (backing)
Asia Regenerative Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Asia Regenerative Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Asia Regenerative Medicine in its N-PORT filings yet. We sweep new filings monthly.